12/2
03:28 pm
nrix
Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast [Yahoo! Finance]
Low
Report
Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast [Yahoo! Finance]
12/1
07:00 am
nrix
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Medium
Report
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
11/25
07:11 am
nrix
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
07:00 am
nrix
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/24
11:00 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $30.00 price target on the stock.
11/10
07:11 am
nrix
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors [Yahoo! Finance]
Low
Report
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors [Yahoo! Finance]
11/10
07:00 am
nrix
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Low
Report
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
11/7
09:00 am
nrix
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
Low
Report
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
11/4
08:09 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $27.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $27.00 price target on the stock.
11/4
08:09 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
11/3
09:00 am
nrix
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Low
Report
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
10/30
07:00 am
nrix
Nurix Therapeutics to Participate in Upcoming Investor Conferences
High
Report
Nurix Therapeutics to Participate in Upcoming Investor Conferences
10/28
08:10 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its price target lowered by analysts at HC Wainwright from $33.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its price target lowered by analysts at HC Wainwright from $33.00 to $28.00. They now have a "buy" rating on the stock.
10/27
07:00 am
nrix
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
Medium
Report
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
10/23
09:33 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its price target lowered by analysts at Wells Fargo & Company from $22.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its price target lowered by analysts at Wells Fargo & Company from $22.00 to $21.00. They now have an "overweight" rating on the stock.
10/23
08:07 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its price target lowered by analysts at BTIG Research from $35.00 to $27.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its price target lowered by analysts at BTIG Research from $35.00 to $27.00. They now have a "buy" rating on the stock.
10/23
06:16 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) was upgraded by analysts at Mizuho to a "strong-buy" rating.
10/22
05:06 pm
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/22
07:20 am
nrix
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Medium
Report
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
10/22
06:00 am
nrix
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Medium
Report
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
10/21
08:03 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $24.00 price target on the stock.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $24.00 price target on the stock.
10/20
08:08 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $27.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $27.00 price target on the stock.
10/20
08:08 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
10/18
09:03 am
nrix
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress [Yahoo! Finance]
10/18
03:00 am
nrix
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
Medium
Report
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress